Araştırma Makalesi

Koroner Arter Hastalarında Lipoprotein (a), Homosistein, Yüksek Duyarlı CReaktif Protein ve Fibrinojen Etkinliğinin Tanısal Değerlendirilmesi

Cilt: 38 Sayı: 4 1 Aralık 2013
Ebru Dundar Yenilmez , Hale Toyaksi , Abdi Bozkurt , Abdullah Tuli , Esmeray Acartürk
PDF İndir
EN TR

Assessment of Diagnostic Efficiency of Lipoprotein (a), Homocysteine, High Sensitive C-Reactive Protein and Fibrinogen in Patients with Coronary Artery Disease

Abstract

Backround: To evaluate the diagnostic value of major and other risk factors as lipoprotein (Lp) (a), homocysteine (Hcy), high sensitive C-reactive protein (hs-CRP) and fibrinogen in CAD patients. Methods: A total of 223 subjects (118 patients and 105 controls) were included in the study according to their coronary angiographic results. Lipoprotein (a), Hcy, hs-CRP and fibrinogen levels were measured using immunoturbidometric, florescent polarization immunoassay and nefelometric methods, respectively. Fasting glucose and lipid parameters, except low density lipoprotein cholesterol (LDL-C), are determined by enzymatic colorimetric methods and the LDL-C levels were calculated by the Fridewald formula. Results: Logistic regression analysis showed that when the biochemical variables in placed in a model, the most important variables were Lp (a), Hcy, hs-CRP and fibrinogen. We showed that each unit of Lp (a), Hcy, hs-CRP and fibrinogen increases the risk of CAD 1.029, 1.177, 1.027 and 1.013 fold, respectively. Among these, fibrinogen level was the most sensitive and efficient parameter in prediction of CAD. Conclusion: Although Lp (a), Hcy, hs-CRP and fibrinogen are independent risk factors for CAD, fibrinogen was the most important one. Fibrinogen can be used as a reliable risk factor for CAD in clinical practice.

Keywords

Coronary artery disease , risk factors , Lipoprotein (a) , Homocysteine , hs-CRP , fibrinogen.

Kaynakça

  1. Robinson K, Mayer EL, Miller D, Green R, van Lente F, Gupta A et al. Hyperhomocysteinemia and low pyridoxal phosphate: common and independent reversible risk factors for coronary artery disease. Circulation. 1995; 92: 2825-30.
  2. Ridker PM. Novel risk factors and markers for coronary disease. Adv in Intern Med. 2000; 45: 3914
  3. McCully KS. Homocystein and vascular disease. Nat Med. 1996; 2: 386-9.
  4. Thambyrajah J, Townend JN, Homocysteine and atherotrhrombosis mechanisms for injury. Eur Heart J. 2000; 21: 967-73.
  5. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men published erratum appears in N Engl J Med. 1997; 337: 356.
  6. Ridker PM, Hennekens CH, Buring JE, Rifai N. Creactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836-43.
  7. Isordia-Salas I, Mendoza-Valez L, Almeida-Gutierrez E, Borrayo-Sanchez G. Genetic factors of hemostatic system in young patients with myocardial infarction. Cir Ciruj. 2010; 78:87-91. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of
  8. Hypertension. J Hypertens. 1999; 17: 151-183.
  9. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). JAMA.2001; 285, 2486-97.
  10. American Diabetes Association, The Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1999; 22: 5-19.

Kaynak Göster

MLA
Yenilmez, Ebru Dundar, vd. “Assessment of Diagnostic Efficiency of Lipoprotein (a), Homocysteine, High Sensitive C-Reactive Protein and Fibrinogen in Patients with Coronary Artery Disease”. Cukurova Medical Journal, c. 38, sy 4, Aralık 2013, ss. 559-66, https://izlik.org/JA38TC63YR.